When treating patients with non-small cell lung cancer (NSCLC) and brain metastases, brain radiotherapy has been the standard option. However, evidence suggests that immunotherapy may improve outcomes, especially when combined with radiotherapy. Studies have shown that pembrolizumab, an immune checkpoint inhibitor, has activity in brain metastases. Combining radiotherapy and immunotherapy has shown a synergistic effect against brain metastases in NSCLC patients. The sequencing of treatments is still debatable, but concurrent administration appears to offer the best outcomes. Although combining the two treatments is generally safe, radiation necrosis can be a concern. More research is needed to determine the optimal approach for treating NSCLC patients with brain metastases.
Source link
Synergy of Combination Therapy for NSCLC Brain Metastases?
